Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: A comparison of evidence-based literature and package insert information

American Journal Geriatric Pharmacotherapy

Volumn 10, Issue 2, 2012, Pages 139-150

  Boyce, Richard D ^a,b   Handler, Steven M ^a,b,c   Karp, Jordan F ^a   Hanlon, Joseph T ^a,b,c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

aged; antidepressants; drug interactions; drug product package inserts; pharmacokinetics

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; METHOTREXATE; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PREDNISONE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE;

AGE DISTRIBUTION; ARTICLE; EMBASE; EVIDENCE BASED PRACTICE; FALLING; FRACTURE; HUMAN; MEDLINE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SCIENTIFIC LITERATURE;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; DRUG INDUSTRY; DRUG INTERACTIONS; DRUG LABELING; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84859533106     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2012.01.001     Document Type: Article

References (109)

1. Hanlon JT, Handler SM, Castle NG. Antidepressant prescribing in US nursing homes between 1996 and 2006 and its relationship to staffing patterns and use of other psychotropic medications. J Am Med Dir Assoc. 2010;11:320-324.
2. Bharucha A, Borson S. Mood disorders. In: Reichman W, Katz P, eds. Psychiatry in Long-Term Care. 2nd ed. New York, N Y: Oxford University Press; 2009:67-128.
3. Pollock B, Forsyth C, Bies R. The critical role of clinical pharmacology in geriatric psychopharmacology. Clin Pharmacol Ther. 2009;85:89-93.
4. Preskorn SH, Flockhart D. 2010 Guide to psychiatric drug interactions. Prim Psychiatry. 2009;16:45-74.
5. Hanlon JT, Wang X, Castle NG, et al. Potential underuse, overuse and inappropriate use of antidepressants in older veteran nursing home patients. J Am Geriatr Soc. 2011;59:1412-1420.
6. Steinmetz KL, Coley KC, Pollock BG. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc. 2005;53:891-894. (Pubitemid 41656940)
7. Hines LE, Ceron-Cabrera D, Romero K, et al. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin Ther. 2011;33:36-45.
8. Chao SD, Maibach HI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol. 2005;6:105-111. (Pubitemid 40529753)
9. Sweetman S. Martindale: The Complete Drug Reference. 36th ed. Palo Alto, Calif: Pharmaceutical Press; 2009.
10. FDA. Drugs@FDA. 2011. http://www.accessdata.fda. gov/scripts/cder/ drugsatfda/. Accessed June 7, 2011.
11. Physicians' Desk Reference. 64th ed. Montvale, NJ: Thomson PDR; 2010.
12. National Library of Medicine. DailyMed. http://dailymed.nlm.nih.gov. Accessed July 1, 2011.
13. Salzman C. Clinical Geriatric Psychopharmacology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004.
14. von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly: Therapeutic implications. Clin Pharmacokinet. 1993;24:141-160. (Pubitemid 23052198)
15. Hrdina PD, Hutchinson LJ, Lapierre YD, et al. Pharmacokinetics of psychotropic drugs: what can it tell us? Prog Neuropsychopharmacol Biol Psychiatry. 1982;6:681-688. (Pubitemid 13146309)
16. Furlanut M, Benetello P. The pharmacokinetics of tricyclic antidepressant drugs in the elderly. Pharmacol Res. 1990;22:15-25. (Pubitemid 20139436)
17. Muijsers RBR, Plosker GL, Noble S. Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging. 2002;19:377-392. (Pubitemid 34804185)
18. Gareri P, Falconi U, De Fazio P, et al. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol. 2000;61:353-396. (Pubitemid 30155726)
19. DeVane CL, Pollock BG. Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry. 1999;60(Suppl 20):38-44. (Pubitemid 29468390)
20. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41:1247-1266. (Pubitemid 36026765)
21. Cutler NR, Narang PK. Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics. Psychiatr Clin North Am. 1984;7:845-861. (Pubitemid 15182004)
22. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997;33:260-275. (Pubitemid 27429893)
23. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206-1227.
24. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005;46:464-494. (Pubitemid 46177967)
25. Ciraulo DA, Shader RI, Greenblatt DJ, et al. Drug Interactions in Psychiatry. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174. (Pubitemid 8054849)
27. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35:876-884.
28. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987;42:193-200. (Pubitemid 17135976)
29. Bayer AJ, Pathy MS, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. Br J Clin Pharmacol. 1983;16:371-376. (Pubitemid 13015760)
30. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996;16: 915-923. (Pubitemid 26322194)
31. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25:183-191. (Pubitemid 36373425)
32. Gutierrez M, Abramowitz W. Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy. 2000;20:1441-1447.
33. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004;44:1352-1359. (Pubitemid 39518640)
34. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet. 1997;32(Suppl 1):22-30. (Pubitemid 27107716)
35. Hrdina PD, Rovei V, Henry JF, et al. Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. Psychopharmacology (Berl). 1980;70: 29-34. (Pubitemid 10052921)
36. Henry JF, Altamura C, Gomeni R, et al. Pharmacokinetics of amitriptyline in the elderly. Int J Clin Pharmacol Ther Toxicol. 1981;19:1-5. (Pubitemid 11160570)
37. Schulz P, Turner-Tamiyasu K, Smith G, et al. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther. 1983;33:360-366. (Pubitemid 13089528)
38. Ogura C, Kishimoto A, Mizukawa R, et al. Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline. Eur J Clin Pharmacol. 1983;25:811-814. (Pubitemid 14212869)
39. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther. 1985;232:183-188. (Pubitemid 15193670)
40. Meyer-Barner M, Meineke I, Schreeb KH, et al. Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol. 2002;58:253-257. (Pubitemid 34827854)
41. Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine - new data and review. Clin Chem. 1988; 34:863- 880.
42. Benetello P, Furlanut M, Zara G, et al. Imipramine pharmacokinetics in depressed geriatric patients. Int J Clin Pharmacol Res. 1990;10:191-195. (Pubitemid 20298664)
43. Jerling M, Merlé Y, Mentré F, et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1994;38:453-462. (Pubitemid 24344034)
44. Dawling S, Crome P, Braithwaite RA, et al. Nortriptyline therapy in elderly patients: dosage prediction after single dose pharmacokinetic study. Eur J Clin Pharmacol. 1980;18:147-150. (Pubitemid 10049065)
45. Wellbutrin SR (bupropion hydrochloride) tablet, film coated [package insert]. Research Triangle Park, NC: GlaxoSmithKline LLC; 2011.
46. Remeron (mirtazapine) tablet, film coated [package insert]. Roseland, NJ: Organon Pharmaceuticals USA; 2011.
47. Cymbalta (duloxetine hydrochloride) capsule, delayed release [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2010.
48. Sertraline hydrochloride tablet [package insert]. Corona, Calif: Watson Laboratories, Inc; 2008. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm? Setid=a8b2ad71-cfdc-4a29-8194-deefea138b16. Accessed July 14, 2011.
49. Azzaro AJ, Ziemniak J,KemperE, et al. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol. 2007;47:146-158. (Pubitemid 46146480)
50. Dostert P, Strolin Benedetti M, Persiani S, et al. Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline. J Neural Transm Suppl. 1995;45:247-257.
51. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol. 1997;20:419-433. (Pubitemid 27424332)
52. Kivistö KT, Wang JS, Backman JT, et al. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. 2001;57:37-42. (Pubitemid 32391410)
53. Kustra R, Corrigan B, Dunn J, et al. Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol. 1999;39:1184-1188. (Pubitemid 30644022)
54. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77:553-559. (Pubitemid 40824968)
55. Farid NA, Payne CD, Ernest CS 2nd, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48:53-59. (Pubitemid 350292280)
56. Hesse LM, Greenblatt DJ, von Moltke LL, et al. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol. 2006;46:567-576.
57. Park J, Vousden M, Brittain C, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol. 2010;50:1180-1187.
58. Sennef C, Timmer CJ, Sitsen JM. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol. 2003; 18:91-101. (Pubitemid 36304723)
59. Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol. 2000;56:389-394. (Pubitemid 30666065)
60. Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol. 2000;14:172-176. (Pubitemid 30389491)
61. Ruwe FJL, Smulders RA, Kleijn HJ, et al. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol. 2001;16:449-459. (Pubitemid 32895588)
62. Barbhaiya RH, Shukla UA, Greene DS. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Br J Clin Pharmacol. 1995;40:161-165.
63. Khan AY, Preskorn SH, Horst WD. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. J Pak Med Assoc. 2007;57:230-235. (Pubitemid 351235483)
64. Laroudie C, Salazar DE, Cosson JP, et al. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. Eur J Clin Pharmacol. 1999; 54:923-928. (Pubitemid 29104412)
65. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: IV A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol. 1995;15:409-416. (Pubitemid 26006343)
66. Farkas D, Volak LP, Harmatz JS, et al. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther. 2009;85:644-650.
67. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Shortterm exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003;43:414-422. (Pubitemid 36368783)
68. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47:191-202.
69. Skinner MH, Kuan H-Y, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-177. (Pubitemid 36269668)
70. Troy SM, Rudolph R, Mayersohn M, et al. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol. 1998;38:467-474. (Pubitemid 28224222)
71. Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol. 2001;21:175-184. (Pubitemid 32221055)
72. Lindh JD, Annas A, Meurling L, et al. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol. 2003;59:401-406. (Pubitemid 37214946)
73. Hynninen V-V, Olkkola KT, Bertilsson L, et al. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther. 2008;83:342-348.
74. Gutierrez M, Abramowitz W. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy. 2001;21:163-168. (Pubitemid 32119193)
75. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol. 2005; 60:287-290. (Pubitemid 41224136)
76. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther. 2003;25:1200-1210. (Pubitemid 36532587)
77. D'Souza DL, Dimmitt DC, Robbins DK, et al. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001;41:455-458. (Pubitemid 32274990)
78. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetics/ pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol. 2004;44: 1252-1259. (Pubitemid 39391484)
79. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;350:102-106. (Pubitemid 19236653)
80. Yasui-Furukori N, Saito M, Inoue Y, et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol. 2007;63:51-56. (Pubitemid 46025473)
81. Nagy CF, Kumar D, Perdomo CA, et al. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol. 2004;58(Suppl 1):25-33.
82. Curry SH, DeVane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29: 429-433. (Pubitemid 16192599)
83. Dugal R, Caille G, Albert JM, et al. Apparent pharmacokinetic interaction of diazepam and amitriptyline in psychiatric patients: a pilot study. Curr Ther Res Clin Exp. 1975;18:679-686.
84. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther. 1996;60:48-53. (Pubitemid 26279220)
85. Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci. 2009;110:98-104.
86. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol. 2001;41:1043-1054. (Pubitemid 32880131)
87. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol. 2002;42:1011-1019. (Pubitemid 34920799)
88. Sauer J-M, Long AJ, Ring B, et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004;308:410-418. (Pubitemid 38134198)
89. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239-248.
90. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14:90-98. (Pubitemid 24120706)
91. Spina E, Avenoso A, Campo GM, et al. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol. 1997;43:315-318. (Pubitemid 27116072)
92. Brøsen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993;44:349-355. (Pubitemid 23153452)
93. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17:284-291. (Pubitemid 27312427)
94. Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol. 2009;64:263-270.
95. Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased doxepin bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. (Pubitemid 16164976)
96. Abernethy DR, Greenblatt DJ, Shader RI. Imipraminecimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229:702-705. (Pubitemid 14076401)
97. Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. (Pubitemid 17021628)
98. Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. (Pubitemid 14150109)
99. Hermann DJ, Krol TF, Dukes GE, et al. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992; 32:176-183.
100. Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res. 1996;59:189-196. (Pubitemid 26058112)
101. Laine K, Tybring G, Härtter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001;70:327-335. (Pubitemid 33022473)
102. Oleptro (trazodone hydrochloride) extended-release tablets [package insert]. Dublin, Ireland: Labopharm; 2010.
103. Effexor (venlafaxine hydrochloride) capsule, extended release [package insert]. Thousand Oaks, Calif: Rebel Distributors Corp; 2010. http://dailymed.nlm.nih. gov/dailymed/lookup.cfm?setid=8a2302ca-5c25-4d2d-9ffe- 320080934aab. Accessed July 14, 2011.
104. Celexa (citalopram hydrobromide) tablet/solution [package insert]. St Louis, Mo: Forest Pharmaceuticals, Inc; 2009. http://dailymed.nlm.nih.gov/ dailymed/ lookup.cfm?setid=4259d9b1-de34-43a4-85a8-41dd21 4e9177. Accessed July 14, 2011.
105. Lexapro (escitalopram oxalate) tablet, film coated/liquid [package insert]. St Louis, Mo: Forest Laboratories, Inc; 2011.
106. Viibryd (vilazodone hydrochloride) tablet, film coated [package insert]. St Louis, Mo: Forest Laboratories Inc; 2011. http://dailymed.nlm.nih.gov/ dailymed/lookup. cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66. Accessed July 14, 2011.
107. de Leon J, Spina E, Diaz FJ. Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing, and translation into a message understandable to practicing clinicians. J Clin Psychopharmacol. 2009;29:201-205.
108. Zint K, Haefeli WE, Glynn RJ, et al. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010; 19:1248 -1255.
109. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364-377.